Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer

Clinical Epigenetics

Volumn 7, Issue 1, 2015, Pages

  Bauden, Monika ^a   Pamart, Dorian ^b   Ansari, Daniel ^a   Herzog, Marielle ^b   Eccleston, Mark ^b   Micallef, Jake ^b   Andersson, Bodil ^a   Andersson, Roland ^a  

^a LUND UNIVERSITY   (Sweden)

^b Belgian Volition SA   (Belgium)

Author keywords

Diagnosis; DNA; Epigenetics; Nucleosomes; NuQ assays; Pancreatic cancer; Screening; Serum

Indexed keywords

CA 19-9 ANTIGEN; TUMOR MARKER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BENIGN TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIGENETICS; FEMALE; HISTONE MODIFICATION; HUMAN; IMMUNOASSAY; MALE; NUCLEOSOME; PANCREAS CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 84943147333     PISSN: 18687075     EISSN: 18687083     Source Type: Journal    
DOI: 10.1186/s13148-015-0139-4     Document Type: Article

References (26)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29. doi:10.3322/caac.21208.
2. Ghatnekar O, Andersson R, Svensson M, Persson U, Ringdahl U, Zeilon P, et al. Modelling the benefits of early diagnosis of pancreatic cancer using a biomarker signature. Int J Cancer. 2013;133(10):2392-7. doi:10.1002/ijc.28256.
3. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33(3):266-70. doi:10.1016/j.ejso.2006.10.004.
4. Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol. 2010;21(3):441-7. doi:10.1093/annonc/mdp332.
5. Omura N, Goggins M. Epigenetics and epigenetic alterations in pancreatic cancer. Int J Clin Exp Pathol. 2009;2(4):310-26.
6. Simmons D. Epigenetic influences and disease. Nature Education. 2008;1(1):6.
7. Neureiter D, Jager T, Ocker M, Kiesslich T. Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects. World J Gastroenterol. 2014;20(24):7830-48. doi:10.3748/wjg.v20.i24.7830.
8. Fullgrabe J, Kavanagh E, Joseph B. Histone onco-modifications. Oncogene. 2011;30(31):3391-403. doi:10.1038/onc.2011.121.
9. Bianco-Miotto T, Chiam K, Buchanan G, Jindal S, Day TK, Thomas M, et al. Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiol Biomarkers Prev. 2010;19(10):2611-22. doi:10.1158/1055-9965.EPI-10-0555.
10. Manuyakorn A, Paulus R, Farrell J, Dawson NA, Tze S, Cheung-Lau G, et al. Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. J Clin Oncol. 2010;28(8):1358-65. doi:10.1200/JCO.2009.24.5639.
11. Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, et al. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog. 2008;47(9):701-6. doi:10.1002/mc.20413.
12. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61(4):1659-65.
13. Mouliere F, Rosenfeld N. Circulating tumor-derived DNA is shorter than somatic DNA in plasma. Proc Natl Acad Sci U S A. 2015;112(11):3178-9. doi:10.1073/pnas.1501321112.
14. Kremer A, Wilkowski R, Holdenrieder S, Nagel D, Stieber P, Seidel D. Nucleosomes in pancreatic cancer patients during radiochemotherapy. Tumour Biol. 2005;26(1):44-9. doi:10.1159/000084339.
15. Wittwer C, Boeck S, Heinemann V, Haas M, Stieber P, Nagel D, et al. Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy. Int J Cancer. 2013;133(11):2619-30. doi:10.1002/ijc.28294.
16. Toiyama Y, Okugawa Y, Goel A. DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer. Biochem Biophys Res Commun. 2014;455(1-2):43-57. doi:10.1016/j.bbrc.2014.08.001.
17. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548-54. doi:10.1038/nm.3519.
18. Holdenrieder S, Stieber P, Bodenmuller H, Busch M, Fertig G, Furst H, et al. Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer. 2001;95(2):114-20.
19. Holdenrieder S, Dharuman Y, Standop J, Trimpop N, Herzog M, Hettwer K, et al. Novel serum nucleosomics biomarkers for the detection of colorectal cancer. Anticancer Res. 2014;34(5):2357-62.
20. Pohar M, Blas M, Turk S. Comparison of logistic regression and linear discriminant analysis: a simulation study. Metodološki zvezki. 2004;1(1):143-61.
21. Kovalchuk O, Tryndyak VP, Montgomery B, Boyko A, Kutanzi K, Zemp F, et al. Estrogen-induced rat breast carcinogenesis is characterized by alterations in DNA methylation, histone modifications and aberrant microRNA expression. Cell Cycle. 2007;6(16):2010-8.
22. Biran A, Meshorer E. Concise review: chromatin and genome organization in reprogramming. Stem Cells. 2012;30(9):1793-9. doi:10.1002/stem.1169.
23. Sims 3rd RJ, Nishioka K, Reinberg D. Histone lysine methylation: a signature for chromatin function. Trends Genet. 2003;19(11):629-39. doi:10.1016/j.tig.2003.09.007.
24. Sporn JC, Jung B. Differential regulation and predictive potential of MacroH2A1 isoforms in colon cancer. Am J Pathol. 2012;180(6):2516-26. doi:10.1016/j.ajpath.2012.02.027.
25. R Core Team. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2013. http://www.R-project.org/.
26. Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifier performance in R. Bioinformatics. 2005;21(20):3940-1. doi:10.1093/bioinformatics/bti623.